CD40L, Soluble, Recombinant, Human (ACRP30headless:CD40L, ACRP30headless:CD154, ACRP30headless:TNFS

CD40L is a high activity construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to combinations. CD40L has shown to suppress alum-induced IL-1beta release and caspase-1 activation in a dose-, CD40- and time dependent manner, without affecting BMDM viability. It also effectively suppressed the inflammasome function triggered by NLRP3 activators. The secretion of caspase-1 independent inflammatory mediators has been shown to be unaltered or even enhanced. Sequence: Human CD40L (aa116-261) is fused at the N-terminus to mouse ACRP30headless (aa18-111) and a FLAG(R)-tag, expressed in CHO cells. Biological Activity: Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86) (ED50: <1ng/ml). Molecular Weight: ~35-40kD (SDS-PAGE), Endotoxin: <0.01EU/ug (LAL test, Lonza). Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.